387867-13-2

Basic information

• Product Name: Tandutinib
• Synonyms: Tandutinib;1-Piperazinecarboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-;4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide;Unii-E1io3icj9a;Tandutinib(CT 53518);Tandutinib (MLN518);4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-Methylethoxy)phenyl]-;N-(4-isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-carboxamide
• CAS NO: 387867-13-2
• Molecular Formula: C31H42N6O4
• Molecular Weight: 562.7
• Product Categories: ZUBRIN;Inhibitors;API;Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors
• Mol File: 387867-13-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 177-178°C
• Boiling Point: 769.5 °C at 760 mmHg
• Flash Point: 419.2 °C
• Appearance: White solid
• Density: 1.213 g/cm³
• Vapor Pressure: 1.35E-23mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 13.39±0.70(Predicted)
• CAS DataBase Reference: Tandutinib(CAS DataBase Reference)
• NIST Chemistry Reference: Tandutinib(387867-13-2)
• EPA Substance Registry System: Tandutinib(387867-13-2)

Safety Data

• Hazardous Substances Data: 387867-13-2(Hazardous Substances Data)

Usage

Description

Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 μM) and does not significantly inhibit other tyrosine or serine/threonine kinases. Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells. It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor. Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 387867-13-2 differently. You can refer to the following data:
1. An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelody
2. antipsoratic
3. An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML w hen administered in combination with cytarabine and daunorubicin.

Definition

ChEBI: An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 s replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.

references

[1] kelly lm1, yu jc, boulton cl, apatira m, li j, sullivan cm, williams i, amaral sm, curley dp, duclos n, neuberg d, scarborough rm, pandey a, hollenbach s, abe k, lokker na, gilliland dg, giese na. ct53518, a novel selective flt3 antagonist for the treatment of acute myelogenous leukemia (aml). cancer cell. 2002 jun;1(5):421-32.

InChI:InChI=1/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)

Upstream product

• 399037-37-7 N-(4-isopropoxyphenyl)piperazine-1-carboxamide hydrochloride 
• 288383-71-1 4-chloro-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazoline 
• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 91203-74-6 4-benzyloxy-3-methoxybenzoic acid benzyl ester 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 110-89-4 piperidine 
• 288383-74-4 6-methoxy-7-(3-piperidinopropoxy)-3,4-dihydroquinazolin-4-one 
• 214470-57-2 methyl 4-(3-chloropropoxy)-5-methoxy-2-nitrobenzoate 
• 111627-40-8 methyl 4-(3-chloropropoxy)-3-methoxybenzoate 
• 7664-66-6 4-(isopropoxy)aniline 
• 927173-22-6 methyl 5-methoxy-2-nitro-4-(3-(piperidin-1-yl)propoxy)benzoate 
• 574738-68-4 methyl 2-amino-5-methoxy-4-(3-(piperidin-1-yl)propoxy)benzoate 
• 948552-60-1 C₁₀H₁₂ClNO₂ 
• 792899-38-8 N-(4-isopropoxyphenyl)piperazine-1-carboxamide 

Relevant articles and documents

LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS

This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a cryst

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib

The synthesis of three substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib (1), erlotinib (2) and gefitinib (3) in improved yields is reported. The intermediates were characterized by NMR and the purities determined by HPLC.